These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study. Zakria M; Hussain A; Ahmad N; Ahmed N; Rauf MA; Siraj S Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4708-4717. PubMed ID: 37259755 [TBL] [Abstract][Full Text] [Related]
6. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin. Zhang D; Ding Y; Wang X; Xin W; Du W; Chen W; Zhang X; Li P Eur J Clin Pharmacol; 2020 Jul; 76(7):939-946. PubMed ID: 32361904 [TBL] [Abstract][Full Text] [Related]
7. An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C. Soko ND; Chimusa E; Masimirembwa C; Dandara C Pharmacogenomics J; 2019 Jun; 19(3):240-248. PubMed ID: 30100615 [TBL] [Abstract][Full Text] [Related]
8. A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics. Soko ND; Masimirembwa C; Dandara C BMC Res Notes; 2018 Jun; 11(1):384. PubMed ID: 29898760 [TBL] [Abstract][Full Text] [Related]
9. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025 [TBL] [Abstract][Full Text] [Related]
10. Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. Kim Y; Yoon S; Choi Y; Yoon SH; Cho JY; Jang IJ; Yu KS; Chung JY Sci Rep; 2019 Dec; 9(1):19410. PubMed ID: 31857620 [TBL] [Abstract][Full Text] [Related]
11. Proteomics-Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight. Wegler C; Prieto Garcia L; Klinting S; Robertsen I; Wiśniewski JR; Hjelmesaeth J; Åsberg A; Jansson-Löfmark R; Andersson TB; Artursson P Clin Pharmacol Ther; 2021 Mar; 109(3):762-771. PubMed ID: 32970864 [TBL] [Abstract][Full Text] [Related]
12. Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. Liu M; Wu XJ; Zhao GL; Zhang T; Xu SS; Sun YX; Qiu F; Zhao LM J Cardiovasc Pharmacol; 2016 Nov; 68(5):383-390. PubMed ID: 27557342 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the Kim CO; Oh ES; Kim H; Park MS Drug Des Devel Ther; 2017; 11():503-512. PubMed ID: 28260863 [TBL] [Abstract][Full Text] [Related]
14. Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Bai X; Zhang B; Wang P; Wang GL; Li JL; Wen DS; Long XZ; Sun HS; Liu YB; Huang M; Zhong SL Acta Pharmacol Sin; 2019 Apr; 40(4):492-499. PubMed ID: 29950617 [TBL] [Abstract][Full Text] [Related]
15. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811 [TBL] [Abstract][Full Text] [Related]
16. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M Br J Clin Pharmacol; 2008 Jan; 65(1):78-86. PubMed ID: 17635496 [TBL] [Abstract][Full Text] [Related]
17. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Xiang Q; Chen SQ; Ma LY; Hu K; Zhang Z; Mu GY; Xie QF; Zhang XD; Cui YM Pharmacogenomics J; 2018 Dec; 18(6):721-729. PubMed ID: 30250148 [TBL] [Abstract][Full Text] [Related]
18. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Lee N; Maeda K; Fukizawa S; Ieiri I; Tomaru A; Akao H; Takeda K; Iwadare M; Niwa O; Masauji T; Yamane N; Kajinami K; Kusuhara H; Sugiyama Y Drug Metab Pharmacokinet; 2019 Dec; 34(6):387-395. PubMed ID: 31594719 [TBL] [Abstract][Full Text] [Related]
19. A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics. Lehtisalo M; Taskinen S; Tarkiainen EK; Neuvonen M; Viinamäki J; Paile-Hyvärinen M; Lilius TO; Tapaninen T; Backman JT; Tornio A; Niemi M Br J Clin Pharmacol; 2023 Jan; 89(1):242-252. PubMed ID: 35942816 [TBL] [Abstract][Full Text] [Related]
20. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Liu JE; Liu XY; Chen S; Zhang Y; Cai LY; Yang M; Lai WH; Ren B; Zhong SL Eur J Clin Pharmacol; 2017 Nov; 73(11):1409-1416. PubMed ID: 28812116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]